Beneficial effects of sucralphate in radiation induced diarrhea. An open randomized study in gynecological cancer patients.
In an open randomized study including 51 consecutive patients with gynaecological malignancies sucralphate was daily administered to patients receiving pelvic irradiation. Sucralphate, an aluminium hydroxide complex of sulphated sucrose used in the treatment of gastric ulcer, seems to be of value in preventing radiation-induced bowel discomfort. The most objective parameter, frequency of diarrhoea was almost 50% less in the sucralphate groups as compared to the controls. The patients receiving sucralphate in general displayed only minor alterations in bowel habits even at the end of the radiation treatment. The number of patients requiring symptomatic therapy with loperamide were markedly lower in the sucralphate group. Subjective discomfort such as nausea, vomiting, loss of appetite were also less common. A reduction in acute reactions to irradiation increases the possibility of carrying through planned treatment and avoids unfavourable intermissions, and thus curing the patient with cancer in the pelvis by means of radiotherapy.
Henriksson
R
R
Department of Oncology, University Hospital Umeă, Sweden.
Arevärn
M
M
Franzén
L
L
Persson
H
H
Stendahl
U
U
D003967:Diarrhea / Q000517:prevention & control*; D005260:Female; D005833:Genital Neoplasms, Female / Q000532:radiotherapy*; D006801:Humans; D011832:Radiation Injuries / Q000517:prevention & control*; D013392:Sucralfate / Q000627:therapeutic use*
D013392:Sucralfate